In the first review of this two-part series, Seiwert and co-authors described the rationale for the use of concurrent chemoradiotherapy for treating malignancies. Here the chemoradiotherapy platforms used for the treatment of head and neck cancer are described and the integration of novel agents such as EGFR inhibitors and antiangiogenic drugs into treatment platforms alongside multiagent-based regimens are reviewed. The authors provide guidance for clinicians based on current clinical trial evidence and suggestions for choosing the most appropriate treatment platform.
- Tanguy Y Seiwert
- Joseph K Salama
- Everett E Vokes
